Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Astellas Pharma bets up to $1.34B to option Audax Biosciences' IL-12 fusion immuno-oncology asset DAX-044
Licensing deal, oncology, antibody, milestone payments, royalties - Read more

Genomate Health, VivaMed BioPharma partner to revive shelved cancer drugs using AI and precision oncology
Research collaboration, oncology, AI/ML, drug discovery, small molecule - Read more

Teva Pharmaceuticals acquires BioXcel's neuroscience portfolio in bankruptcy sale for $125M
Acquisition, neurological, small molecule, milestone payments - Read more

Enveda, Anthropic collaborate using Claude AI to accelerate drug regulatory documentation and quality review workflows
Research collaboration, AI/ML, regulatory, drug discovery, manufacturing - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Vanda Pharmaceutical's Nereus targets GLP-1 receptor agonist-induced nausea and vomiting label expansion after Ph3 win
Small molecule, metabolic, NK-1 receptor antagonist, GLP-1 therapy, nausea and vomiting - Read more

Eli Lilly's (retatrutide) beats Novo's Ozempic in Ph3 trial for type 2 diabetes on blood sugar and weight loss
Small molecule, metabolic, type 2 diabetes, GLP-1 agonist, obesity, retatrutide - Read more

Genmab's (petosemtamab) hits overall survival endpoint in Ph3 for PD-L1-positive head and neck squamous cell carcinoma
Antibody, cancer, bispecific antibody, head and neck squamous cell carcinoma, EGFR, combination therapy - Read more

Biogen posts third consecutive quarter of revenue growth, reaching $2.8B with Apellis integration boost
Antisense oligonucleotide, neurological, revenue impact, financial - Read more

Ferring Pharmaceuticals to acquire Gameto for up to $1.4B, adding next-gen IVF technology Fertilo
Cell therapy, reproductive health, major transaction, strategic - Read more

FDA issues draft guidance to streamline personalized gene therapy approvals, expanding patient access to rare disease treatments
Gene therapy, rare disease, regulatory, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

GSK vaccine sales miss Q3 expectations amid falling adult market demand, raising oncology pivot concerns
Vaccine, infectious disease, financial, competitive - Read more

Teva to close underutilized New Jersey plant, laying off 61 employees by early 2027
Generic drugs, operational, cost reduction, manufacturing - Read more

GSK confirms limited UK job cuts in headquarters as global restructuring targets £1.9B ($2.1B) savings
Restructuring, vaccines, cost reduction, operational, strategic - Read more

Fractyl Health, EyePoint each cut ~50% of workforce, refocusing pipelines amid clinical setbacks
Gene therapy, ophthalmology, cost reduction, operational - Read more

Amgen receives FDA warning letter for Vectibix promotional video omitting critical risk information
Monoclonal antibody, oncology, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here